Department of Dermatology and Allergy, Cantonal Hospital of St Gallen, Switzerland.
Mult Scler. 2011 Nov;17(11):1390-2. doi: 10.1177/1352458511411062. Epub 2011 Jul 5.
Glatiramer acetate (Copaxone(®)) is an immunomodulatory polypeptide used in patients with relapsing-remitting multiple sclerosis. It represents a safe treatment option with mild side effects. In this study, we look at a 39-year-old woman who received glatiramer acetate as subcutaneous injections for two months and developed contact dermatitis. The drug had to be stopped, and treatment with topical prednisone was initiated. Prick/scratch testing was negative but the lymphocyte transformation test was highly positive for glatiramer acetate. This is the first report on contact dermatitis induced by glatiramer acetate injections. The treatment consisted of local topical steroids and cessation of the drug.
醋酸格拉替雷（Copaxone(®)）是一种用于治疗复发缓解型多发性硬化症的免疫调节多肽药物。它是一种安全的治疗选择，副作用轻微。在本研究中，我们观察了一名 39 岁女性，她接受了两个月的醋酸格拉替雷皮下注射治疗，结果发生了接触性皮炎。药物不得不停止使用，开始局部使用泼尼松进行治疗。皮内/划痕试验为阴性，但淋巴细胞转化试验对醋酸格拉替雷呈高度阳性。这是首例关于醋酸格拉替雷注射引起接触性皮炎的报告。治疗包括局部使用皮质类固醇和停止使用该药物。
